Presentation is titled “Clinical development of oncolytic virus therapies using nonpathogenic Seneca Valley Virus platform”
PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers will be presenting on Wednesday, April 20 at 12:10pm at the World Vaccine Congress in Washington, DC. Seneca Therapeutics’ Senior Immunology Consultant, Michael Lacy, PhD will present a summary of prior research and three clinical trials done utilizing Seneca Valley Virus (SVV-001) delivered intravenously as a monotherapy. These clinical trials demonstrated profound tumor selectivity and safety. Dr. Lacy will also discuss Seneca’s upcoming Phase I/II clinical trial in both Neuroendocrine tumor and carcinoma patients. This trial combines intratumoral administration of SVV-001 with anti-PD1 and anti-CTLA4 checkpoint inhibitors. Finally, data will also be presented demonstrating the utility of SVV to express therapeutic transgenes (armed derivatives) and/or cancer antigens.
About Seneca Therapeutics
Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.
Contacts
Paul Hallenbeck
CSO and President
phallenbeck@senecatherapeutics.com
James Hussey
CEO
jhussey@senecatherapeutics.com